Effectiveness of Sitagliptin in Glycemic Control in Real World

A Retrospective, Observational Study to Assess the Effectiveness of Glycemic Control of Diabetes in Real World After Sitagliptin Usage

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01316835

Enrollment

1120

Registered

2011-03-16

Start date

2010-12-31

Completion date

2011-12-31

Last updated

2011-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Keywords

retrospective,sitagliptin, glycemia control,real world

Brief summary

This study will evaluate whether the addition of sitagliptin treatment provides additional decrease in HbA1C levels and increase in goal attainment in patients with inadequate glycemic control on their current oral anti-glycemic therapy in real world practice.

Detailed description

To explore the change of glycemic control (HbA1c or FPG) before and after 24 weeks of Sitagliptin treatment in Type 2 Diabetic patients who have started Sitagliptin as add on therapy during the index period and received Sitagliptin continuously\* for at least 24 weeks.

Interventions

None listed

Study design

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

1. All subjects diagnosed of type 2 diabetes (ICD-9 code= 250.0; 250.1; 250.2; 250.3; 250.4; 250.5; 250.6) and have been followed up regularly in the study center who have started to receive Sitagliptin as an add-on treatment to their prior regimen during the index period 2. Subjects must be on a stable dose of all antidiabetic regimens, with stable dose defined as at least 3 months with no therapy/dose change prior to adding sitagliptin 3. Subjects in whose medical records a minimum core data set can be found. 4. Outpatient

Exclusion criteria

1. Subjects with type 1 DM 2. Subjects have been treated with insulin regularly 3. Subject with DM which results from other general diseases, e.g. surgery, pharmaceutical products, malnutrition, infections and other conditions 4. Subjects who participated in a clinical trial or other clinical study during the index period

Countries

Taiwan

Contacts

Primary ContactChing-Jung Hsieh, MD

rose@adm.cgmh.org.tw886-7-7317123

Outcome results